<DOC>
	<DOCNO>NCT01039090</DOCNO>
	<brief_summary>In Parkinson 's disease , treatment mainly aim improve motor function . However , dysfunction often observe Parkinson 's patient , may important consequence quality life patient . Cognitive neuropsychological trouble may observe , memory impairment anxiety example . As kind trouble worry patient ( ) his/her family , treatment need take account trouble addition motor difficulty . In centre , already use continuous Apomorphine infusion among Parkinson 's patient seem good result . The present study aim objectively assess efficacy continuous Apomorphine infusion cognitive neuropsychological function Parkinson 's disease use clinical positron emission tomography ( PET ) -scan measure .</brief_summary>
	<brief_title>Efficacy Continuous Apomorphine Infusion Cognitive Neuropsychological Functions Parkinson 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Apomorphine</mesh_term>
	<mesh_term>Dopamine Agonists</mesh_term>
	<mesh_term>Dopamine</mesh_term>
	<mesh_term>Dopamine Agents</mesh_term>
	<criteria>Age 18 Parkinson 's disease accord UKPDSBB diagnosis criterion Motor difficulty spite dopaminergic per o treatment Not eligible deep brain stimulation one reason ( age &gt; 70 , axial trouble spite dopaminergic per o treatment , cognitive trouble and/or hallucination ) Mattis scale &lt; 120 Contraindication Apomorphine ( liver insufficiency , severe cognitive trouble , allergy , pregnancy , neuroleptic treatment ) Contraindication FluoroDeoxyGlucose use PETScan ( allergy , kidney failure , pregnancy , breast feeding )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>Not eligible deep brain stimulation</keyword>
	<keyword>Parkinsons 's patient</keyword>
</DOC>